Stuart  Cobb net worth and biography

Stuart Cobb Biography and Net Worth

Chief Scientific Officer of Neurogene

Stuart Cobb, Ph.D., is Chief Scientific Officer at Neurogene. Dr. Cobb, who joined Neurogene in 2019, brings to the team more than 20 years of experience in translational neuroscience. He leads Neurogene’s scientific research, the development of scientific strategy to support the company’s existing and growing gene therapy portfolio, and efforts to identify novel technologies that complement Neurogene’s pipeline. In addition to his role at Neurogene, Dr. Cobb also leads a research team at the University of Edinburgh, where he is Professor of Translational Neuroscience at Simons Initiative in the Developing Brain and Centre for Discovery Brain Sciences. Prior to his work at Neurogene, Dr. Cobb was a Caledonian Research Fellow and led an academic research laboratory at the University of Glasgow. His research has focused on developing novel genetic treatments for brain disorders based on a deep understanding of the molecular and cellular pathology. Dr. Cobb’s work has been published in leading journals and includes seminal work on the inherent reversibility of neurological features in neurodevelopmental disease. Dr. Cobb has a B.Sc. from the University of Glasgow and a Ph.D. in Neuroscience from the University of Oxford.

What is Stuart Cobb's net worth?

The estimated net worth of Stuart Cobb is at least $621.53 thousand as of March 13th, 2026. Dr. Cobb owns 30,497 shares of Neurogene stock worth more than $621,529 as of April 11th. This net worth approximation does not reflect any other assets that Dr. Cobb may own. Learn More about Stuart Cobb's net worth.

How do I contact Stuart Cobb?

The corporate mailing address for Dr. Cobb and other Neurogene executives is 535 W 24th Street, 5th Floor, New York, NY 10011, United States. Neurogene can also be reached via phone at (877) 237-5020 and via email at [email protected]. Learn More on Stuart Cobb's contact information.

Has Stuart Cobb been buying or selling shares of Neurogene?

Stuart Cobb has not been actively trading shares of Neurogene during the past quarter. Most recently, Stuart Cobb sold 6,797 shares of the business's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a transaction totalling $141,445.57. Following the completion of the sale, the insider now directly owns 30,497 shares of the company's stock, valued at $634,642.57. Learn More on Stuart Cobb's trading history.

Who are Neurogene's active insiders?

Neurogene's insider roster includes Stuart Cobb (Chief Scientific Officer), and Rachel McMinn (CEO). Learn More on Neurogene's active insiders.

Are insiders buying or selling shares of Neurogene?

In the last year, insiders at the sold shares 3 times. They sold a total of 17,639 shares worth more than $328,596.57. The most recent insider tranaction occured on March, 13th when insider Stuart Cobb sold 6,797 shares worth more than $141,445.57. Insiders at Neurogene own 11.6% of the company. Learn More about insider trades at Neurogene.

Information on this page was last updated on 3/13/2026.

Stuart Cobb Insider Trading History at Neurogene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2026Sell6,797$20.81$141,445.5730,497View SEC Filing Icon  
5/14/2025Sell6,797$15.15$102,974.5520,794View SEC Filing Icon  
See Full Table

Stuart Cobb Buying and Selling Activity at Neurogene

This chart shows Stuart Cobb's buying and selling at Neurogene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurogene Company Overview

Neurogene logo
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $20.38
Low: $19.92
High: $21.49

50 Day Range

MA: $19.95
Low: $16.37
High: $23.91

2 Week Range

Now: $20.38
Low: $8.99
High: $37.27

Volume

120,119 shs

Average Volume

141,533 shs

Market Capitalization

$317.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56